Protagonist Therapeutics: CFO Ali Asif exercised 58,629 shares

What happened

• The filing shows Ali Asif, chief financial officer, exercised options to acquire 58,629 shares and sold 58,629 shares on Sep 30, 2026. The exercises required cash payments totaling $1,390,735; the reported sale proceeds total $8,312,294.

Key details

• Transaction date: Sep 30, 2026.
• Option exercises (code M): 9,229 shares at $38.98 for $359,746; 28,438 shares at $23.42 for $666,018; 15,650 shares at $19.19 for $300,324; 5,312 shares at $12.17 for $64,647.
• Open market sales (code S): 12,595 shares sold at a weighted average price of $141.77 for $1,785,593; 46,034 shares sold at a weighted average price of $141.78 for $6,526,701. Footnotes report the sales were executed in multiple transactions at price ranges of $140.21–$143.31 and $140.16–$143.45 (F2, F3).
• Footnotes: transactions were effected under a Rule 10b5-1 trading plan adopted Jun 30, 2026 (F1). The filing includes option vesting notes for related grants (F4–F7), including one option identified as fully vested (F6).
• Shares owned after the transaction: not reported in the provided summary.
• Filing date: Oct 2, 2026 (as filed with the SEC).

Why it may matter

• The filing shows exercised options and that the exercised shares were sold the same day, consistent with a cashless exercise/sale on Sep 30, 2026.
• This filing does not show why the insider traded or why the company acted.